posted
China Health Holding Announces Execution of Acquisition Letter of Intent to Acquire 51% or More of Beijing Boran Pharmaceutical Oct 16, 2006 9:48:00 AM Copyright Business Wire 2006
--(BUSINESS WIRE)--
Julianna Lu, the Founder/CEO of China Health Holding (the Company) (OTCBB:CHHH), a development stage company with the goal of becoming an undisputed leading developer, manufacturer, marketer and distributor in the global medical and pharmaceutical industry in China and worldwide, announced today that the Company has executed a Letter of Intent with Beijing Boran Pharmaceutical Co. Ltd. (PR China) for the proposed acquisition by the Company of 51% or more of Beijing Boran Pharmaceutical Co. Ltd.
Pursuant to the Letter of Intent, the parties have expressed further cooperation and accomplishment of the 51% or more acquisition of Beijing Boran Pharmaceutical Co. Ltd. by the Company. Further, Beijing Boran Pharmaceutical Ltd. has agreed to offer the Company first refusal rights and legal exclusive rights for 51% or more of Beijing Boran Pharmaceutical Co. Ltd. within nine months from the dated and signed Letter of Intent. The completion of the acquisition is subject to the negotiation and execution of a definitive acquisition agreement, as well as the completion of full legal and financial due diligence, including the determination of the valuation of Beijing Boran Pharmaceutical Co. Ltd., and the completion and delivery of audited financial statements of Beijing Boran Pharmaceutical Co. Ltd. The acquisition contemplated by the Letter of Intent with Beijing Boran Pharmaceutical Co. Ltd. is part of the Company's comprehensive growth strategy. Management believes that its strategy of pursuing the strategic combination of assets and net income and unique enhanced China-SFDA licensed pharmaceutical drug pipeline and technologies will accrete value to the Company and its shareholders. Management also believes that its acquisition growth strategy will assist the Company in securing a strong future and powerful position in the global and Chinese natural medicinal and pharmaceutical industries.
About Beijing Boran Pharmaceutical Co. Ltd.
Beijing Boran Pharmaceutical Co. Ltd., a China -- SFDA licensed GMP pharmaceutical drug (herbal-based) corporation, as well as a pharmaceutical manufacturer, researcher and developer, is headquartered in Beijing PR China with approximately 7300 square meters of land and a total of 2100 square meters of facilities and buildings. With the most advanced pharmaceutical GMP manufacturing facilities/technologies and technical teams, Beijing Boran Pharmaceutical also controls and owns subsidiary companies, including Beijing Aokai Pharmaceutical and Medical Research Institution, Beijing Xiangwei Herbal Medicinal Co. Ltd., and Beijing Boran Pharmaceutical and Medical Development Co. Ltd., etc. Beijing Boran Pharmaceutical has about 30 pharmaceutical drug (herbal-based)pipelines licensed by China-SFDA.
About China Health Holding, Inc.
China Health Holding, Inc. has an extensive knowledge of and expertise in the field of Traditional Chinese Medicine and the China pharmaceutical industry, which it uses to develop, manufacture, and commercialize natural herbal medicinal products and pharmaceutical drug pipelines and technologies worldwide.
CHHH's immediate goal is profitable penetration of the growing global and China pharmaceutical industry and market. Also to seek and develop and complete potential acquisition candidates with major pharmaceutical companies in PR China and worldwide to secure a strong future and powerful position in the global and PR China pharmaceutical industry. Long-term plans include the development of a pharmaceutical drug pipeline and technology based on the Company's access to the knowledge of Traditional Chinese Medicine and PR China pharmaceutical industry.
CHHH is supported by two core, wholly owned subsidiaries:
1. China Health World Pharmaceutical Corporation, which will develop, manufacture and commercialize natural medications for epidemic diseases and conditions related to mellitus, cardiovascular and cerebral-vascular system dysfunctions, and neurological disorders.
2. China Health World Trade Corporation, which will support CHHH in the areas of worldwide retain/franchise stores/infrastructure and worldwide branding, multimedia marketing and multi-channel distribution to global customers and markets.
Recent Developments and Acquisition Progress:
1. The Company controls/owns exclusive worldwide ownership/rights for a total of 134 proprietary natural herbal medicinal products/formulas as Two Natural Herbal Medicinal Product lines: King of Herbs products and Taoist Medicinal products. The Company is developing and execution for further worldwide branding, multimedia marketing and multi-channel distribution, and worldwide retail and franchise stores/infrastructure to global customers and markets.
2. CHHH has executed a definitive acquisition agreement to acquire 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd.
3. CHHH has executed a definitive acquisition agreement to acquire 100% of Shaanxi MeiChen Pharmaceuticals Co. Ltd.
4. CHHH recently entered into letters of intent to acquire 51% or more of the following pharmaceutical companies in PR China:
i. Shaanxi Wanan Pharmaceuticals Co. Ltd.
ii. Henan Tiankang Pharmaceuticals Co. Ltd.
CHHH believes that the completion of these acquisitions will enable it to vertically integrate its operations from manufacturing, developing and marketing Chinese herbal-based medicinal products, as well as a pharmaceutical drug pipeline, to full distribution and marketing across PR China, therefore substantially increasing profit margins. Acquisitions should accelerate growth of revenues and earnings. A strategic combination of assets, net income, an enhanced pharmaceutical drug pipeline and technologies will accrete value to the Company and its shareholders.
In addition, CHHH also recently signed a letter of intent with WangJing Hospital and the WangJing Hospital of China Academy of Chinese Medical Sciences, PR China, in order to develop the China International University of Traditional Chinese Medicine and the University Hospital for Traditional Chinese Medical Sciences.
IP: Logged |
China Health Holding Attends National Investment Banking Association Conference in Las Vegas Nov 18, 2006 3:20:00 PM Copyright Business Wire 2006
LAS VEGAS--(BUSINESS WIRE)--
China Health Holding (OTCBB: CHHH), a developer, manufacturer, marketer and distributor in the global medical and pharmaceutical industry in China and worldwide, announced today the Company's Founder/CEO Julianna Lu will attend the National Investment Banking Association Conference in Las Vegas, NV on Nov. 30 - Dec. 1, 2006, to raise the Company's profile and visibility on Wall Street. National Investment Banking Association (NIBA) is a national trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. NIBA member firms have successfully completed some 850+ equity offerings totaling approximately $9 billion in new capital for America's finest emerging growth companies.
Currently, Los Angeles-based Investor Relations International ("IRI", www.irintl.com), as investor relations counsel/partner for the Company, is executing a three (3) years long term IR Program to raise investor awareness of the company's performance through a multi-channel campaign. IRI will employ print and electronic media as well as direct communication with money managers and current or prospective shareholders. The IRI program, focused on communicating China Health's expansion strategy across China, seeks both to broaden the Company's shareholder base and to solidify the long-term loyalty of current shareholders. The one crucial element we have lacked up to this point is a strong investor-relations program to raise our profile on Wall Street and give us better access to the capital markets should we require it. Our IR partnership with IRI fills that gap, and we expect to benefit from much greater visibility and liquidity from here on. If you would like to be added to China Health's investor email lists or have additional questions, please contact Haris Tajyar with Investor Relations International at htajyar*irintl.com, or/and info*chinahealthholding.com.
IP: Logged |
quote:Originally posted by zigster: jonus you lousy pumper stop trying to help a shady overseas company steal money from hard working americans
LMAO.. let's see.. you are in RSHN? for over 6mo now.. oh, and PGPM, OH!!! AND.. la creme da la creme.. JMCP.. and all your posts, except for 2 today were in June-July? I'm not in CHHH.. but after Jonus POSTED all the HELPFUL DD, I wish I did. Where were you? Maximum security? I hate to inform you, but this is a big world now AND it includes China, all of Europe, etc etc.. including America (notice the capital "A" which America deserves). So why don't you get off your high horse..because I'm sure you ran out of quarters by now.
-------------------- "As long as there are dreamers, there are dreams that will come true."
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
